Ipsogen Accelerates Its Development in Europe with the CE marking of its JAK2 Diagnostic Kits
News Jul 01, 2008
IPSOGEN SA has announced the CE marking of its JAK2 tests for myeloproliferative disorders.
The CE marking is a major requirement for the European Community regulation and the 98/79/CE directives for in vitro diagnostics medical devices.
These kits that were designed for Research Use Only (RUO) have now reached a regulatory status enabling a wider diagnostic use. JAK2 testing has revolutionized the diagnosis of this group of diseases that affect more than 40,000 Europeans every year.
Ipsogen is the exclusive worldwide licensee of the intellectual property on JAK2V617F mutation discovered by the INSERM team of Dr. Vainchenker at Institut Gustave Roussy, Paris, France.
This mutation plays a key role in the development of myeloproliferative disorders including Polycythemia Vera (PV), Idiopathic Myelofibrosis (IMF) and Essential Thrombocythemia (ET).
Ipsogen has developed a comprehensive range of tests enabling the indentification and the quantification of this mutation (JAK2 MutaScreen™ and JAK2 MutaQuant™ ranges, respectively).
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Synthetic Biology Breakthrough Means Bacteria Could Produce Our Essential DrugsNews
Bacteria could be programmed to efficiently produce drugs, thanks to breakthrough research into synthetic biology using engineering principles.READ MORE
Comments | 0 ADD COMMENT
Highly Potent Active Pharmaceutical Ingredients (HPAPI)
May 21 - May 22, 2018